TransMedics [TMDX] vs Penumbra [PEN] Detailed Stock Comparison
TransMedics
NASDAQ
Loading...
Penumbra
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: TransMedics wins in 7 metrics, Penumbra wins in 12 metrics, with 0 ties. Penumbra appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | TransMedics | Penumbra | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 59.92 | 67.16 | TransMedics |
| Price-to-Book Ratio | 12.76 | 7.63 | Penumbra |
| Debt-to-Equity Ratio | 163.10 | 17.04 | Penumbra |
| PEG Ratio | 0.34 | -0.39 | Penumbra |
| EV/EBITDA | 42.88 | 54.69 | TransMedics |
| Profit Margin (TTM) | 13.49% | 11.54% | TransMedics |
| Operating Margin (TTM) | 23.24% | 12.03% | TransMedics |
| EBITDA Margin (TTM) | 23.24% | 12.03% | TransMedics |
| Return on Equity | 28.21% | 12.03% | TransMedics |
| Return on Assets (TTM) | 5.80% | 6.20% | Penumbra |
| Free Cash Flow (TTM) | $-80.94M | $147.30M | Penumbra |
| 1-Year Return | -32.36% | 19.63% | Penumbra |
| Price-to-Sales Ratio (TTM) | 7.65 | 7.71 | TransMedics |
| Enterprise Value | $4.30B | $9.67B | Penumbra |
| EV/Revenue Ratio | 8.09 | 7.55 | Penumbra |
| Gross Profit Margin (TTM) | 61.38% | 65.99% | Penumbra |
| Revenue per Share (TTM) | $16 | $33 | Penumbra |
| Earnings per Share (Diluted) | $1.99 | $3.77 | Penumbra |
| Beta (Stock Volatility) | 2.09 | 0.40 | Penumbra |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
TransMedics vs Penumbra Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| TransMedics | -2.52% | -8.42% | 14.67% | -2.06% | 65.13% | 78.66% |
| Penumbra | -1.70% | -0.73% | 9.84% | -7.03% | -13.82% | 4.74% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| TransMedics | -32.36% | 127.30% | 568.22% | 379.07% | 379.07% | 379.07% |
| Penumbra | 19.63% | 51.55% | 13.77% | 508.64% | 508.64% | 508.64% |
Performance & Financial Health Analysis: TransMedics vs Penumbra
| Metric | TMDX | PEN |
|---|---|---|
| Market Information | ||
| Market Cap | $4.07B | $9.87B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 866,924 | 333,680 |
| 90 Day Avg. Volume | 1,217,355 | 478,483 |
| Last Close | $118.81 | $251.37 |
| 52 Week Range | $55.00 - $177.37 | $184.80 - $310.00 |
| % from 52W High | -33.02% | -18.91% |
| All-Time High | $177.37 (Aug 19, 2024) | $348.67 (Jun 26, 2023) |
| % from All-Time High | -33.02% | -27.91% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.38% | 0.13% |
| Quarterly Earnings Growth | 1.86% | 0.13% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.12% |
| Operating Margin (TTM) | 0.23% | 0.12% |
| Return on Equity (TTM) | 0.28% | 0.12% |
| Debt to Equity (MRQ) | 163.10 | 17.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $9.35 | $33.20 |
| Cash per Share (MRQ) | $11.75 | $10.89 |
| Operating Cash Flow (TTM) | $115.27M | $201.49M |
| Levered Free Cash Flow (TTM) | $-7,754,500 | $97.77M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: TransMedics vs Penumbra
| Metric | TMDX | PEN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 59.92 | 67.16 |
| Forward P/E | 72.27 | 66.98 |
| PEG Ratio | 0.34 | -0.39 |
| Price to Sales (TTM) | 7.65 | 7.71 |
| Price to Book (MRQ) | 12.76 | 7.63 |
| Market Capitalization | ||
| Market Capitalization | $4.07B | $9.87B |
| Enterprise Value | $4.30B | $9.67B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 8.09 | 7.55 |
| Enterprise to EBITDA | 42.88 | 54.69 |
| Risk & Other Metrics | ||
| Beta | 2.09 | 0.40 |
| Book Value per Share (MRQ) | $9.35 | $33.20 |
Financial Statements Comparison: TransMedics vs Penumbra
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TMDX | PEN |
|---|---|---|
| Revenue/Sales | $143.54M | $324.14M |
| Cost of Goods Sold | $55.31M | $108.26M |
| Gross Profit | $88.23M | $215.88M |
| Research & Development | $17.16M | $22.08M |
| Operating Income (EBIT) | $27.44M | $40.35M |
| EBITDA | $36.27M | $49.20M |
| Pre-Tax Income | $26.68M | $43.86M |
| Income Tax | $994,000 | $4.64M |
| Net Income (Profit) | $25.68M | $39.22M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TMDX | PEN |
|---|---|---|
| Cash & Equivalents | $310.14M | $376.05M |
| Total Current Assets | $505.92M | $999.71M |
| Total Current Liabilities | $55.60M | $158.63M |
| Long-Term Debt | $515.62M | $205.85M |
| Total Shareholders Equity | $266.31M | $1.21B |
| Retained Earnings | $-442.56M | $99.23M |
| Property, Plant & Equipment | $40.54M | $274.92M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TMDX | PEN |
|---|---|---|
| Operating Cash Flow | $354,000 | $46.01M |
| Capital Expenditures | $-27.04M | $-13.47M |
| Free Cash Flow | $-29.89M | $35.50M |
| Debt Repayment | N/A | $-613,000 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TMDX | PEN |
|---|---|---|
| Shares Short | 7.67M | 1.52M |
| Short Ratio | 6.69 | 3.07 |
| Short % of Float | 0.39% | 0.05% |
| Average Daily Volume (10 Day) | 866,924 | 333,680 |
| Average Daily Volume (90 Day) | 1,217,355 | 478,483 |
| Shares Outstanding | 33.62M | 38.49M |
| Float Shares | 32.96M | 37.83M |
| % Held by Insiders | 0.03% | 0.04% |
| % Held by Institutions | 1.13% | 0.94% |
Dividend Analysis & Yield Comparison: TransMedics vs Penumbra
| Metric | TMDX | PEN |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |